ORPHA:66628
Obesity due to congenital leptin deficiency
Publications
701
Trials
0
Interventional, condition-specific
Researchers
973
Distinct authors in sample
Gene link
LEP
Definitive
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
leptin deficiency is a form of monogenic obesity characterised by severe early-onset obesity and marked hyperphagia.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0013991
- OMIM:614962
- UMLS:C3554224
Additional Mondo synonyms (2)
Congenital Leptin Deficiency · obesity, morbid, due to leptin deficiency
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Definitive — LEP
- LiteraturePresent
701 matched papers (360 in last 10 years) Source
- Phenotype characterisedPresent
31 HPO annotations (e.g. Decreased total CD4+ T cell proportion; Decreased serum leptin; Gynecomastia) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (LEP).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
31
Associated phenotypes · MONDO:0013991
- Decreased total CD4+ T cell proportion
- Decreased serum leptin
- Gynecomastia
- Primary amenorrhea
- Polyphagia
Showing 5 of 31 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
701
701 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
701 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
360 in the last 10 years · low confidence
Phrase hits: 657 · MeSH hits: 0
Who's working on it?
973
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Wabitsch M18 papers · 2025
Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics and Adolescent Medicine, University Hospital Ulm, Ulm, Germany.
Papers in Europe PMC - 02von Schnurbein J11 papers · 2024
Division of Pediatric Endocrinology and Diabetes (M.W., J.-B.F., J.v.S., F.D., C.D., A.M., P.F.-P.), and Department of Pediatrics and Adolescent Medicine (G.L., K.-M.D.), University Medical Center Ulm, 89075 Ulm, Germany; Clinical Genetics Department (I.M., M.E.), National Research Center, Cairo 12311, Egypt; Institute of Pharmacology and Toxicology (P.G., B.M.), University Medical Center Ulm, 89081 Ulm, Germany; and University of Cambridge Metabolic Research Laboratories (V.M., J.M.K., I.S.F.), Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge CB2 0QQ, United Kingdom.
Papers in Europe PMC - 03Fischer-Posovszky P10 papers · 2024
Department of Pediatrics and Adolescent Medicine, University of Ulm, Ulm, Germany.
Papers in Europe PMC - 04Hebebrand J10 papers · 2025
Department of Child and Adolescent Psychiatry, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Papers in Europe PMC - 05Farooqi IS8 papers · 2026
Metabolic Research Laboratory, Institute of Metabolic Science, University of Cambridge, Cambridge, United Kingdom
Papers in Europe PMC - 06Antel J7 papers · 2025
Department of Child and Adolescent Psychiatry, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Papers in Europe PMC - 07Brandt S7 papers · 2024
Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Eythstr. 24, D-89075, Ulm, Germany.
Papers in Europe PMC - 08Brown RJ7 papers · 2025
a Diabetes, Endocrinology, and Obesity Branch , National Institute of Diabetes and Digestive Kidney Diseases, National Institutes of Health , Bethesda , MD , USA.
Papers in Europe PMC - 09Mantzoros CS7 papers · 2024
Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, ST 820, Boston, MA 02215, USA. Electronic address: cmantzor@bidmc.harvard.edu.
Papers in Europe PMC - 10Hinney A6 papers · 2025
Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital Essen, University of Duisburg-Essen, Virchowstraße 174, 45147, Essen, Germany.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name. 1 observational study did — shown below because natural-history and cohort work can be an important step toward a trial.
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
low confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 61 · after dedupe 54 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 54 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (54)
- isrctn·ISRCTN83599025·No longer recruiting·GIFTS: Mother and Child Health Study
skipped — LLM skipped (--skip-llm)
- ctis·2024-518674-14-00·Authorised·An Open-Label Study of Mibavademab (REGN4461), a Leptin Receptor Agonist, for the Treatment of Monogenic Obesity Due to Biallelic Loss of Function Variants of the LEP Gene
skipped — LLM skipped (--skip-llm)
- ctis·2025-522488-14-00·Authorised·A clinical study to compare efficacy and safety of two different doses of CagriSema and semaglutide in participants with obesity with or without type 2 diabetes
skipped — LLM skipped (--skip-llm)
- ctis·2025-524688-19-00·Authorised·A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Master Protocol to Evaluate the Efficacy and Safety of Elecoglipron in Participants with Obesity or Overweight with or without Type 2 Diabetes Mellitus (Embold)
skipped — LLM skipped (--skip-llm)
- ctis·2025-524249-29-00·Authorised·A placebo-controlled comparability study to compare two presentations of cagrilintide for weight management in participants with overweight or obesity
skipped — LLM skipped (--skip-llm)
- ctis·2026-526307-30-00·Authorised·A study to compare how 2 different formulations of survodutide are taken up in the body when given by injection in healthy men and women with and without overweight or obesity
skipped — LLM skipped (--skip-llm)
- ctis·2026-526334-67-00·Authorised, recruiting·C6501003 - A Phase 1, Open-Label, Randomized, Single Dose, Parallel Group Study to Assess Relative Bioavailability of PF-08653945 When Administered Across Different Injection Sites in Adults With Overweight or Obesity
skipped — LLM skipped (--skip-llm)
- ctis·2026-525500-10-00·Authorised·ObStructive Sleep Apnoea ManageMent in Older AdUlts with Overweight or ObEsity: A Randomized ClinicaL Trial (SAMUEL study)
skipped — LLM skipped (--skip-llm)
- ctis·2026-525179-26-00·Authorised, ongoing·A study to see how safe a new medicine (NNC6022-0004) is in healthy people and people living with obesity
skipped — LLM skipped (--skip-llm)
- ctis·2026-526016-36-00·Authorised·A neuropsychobiological approach to optimize patient selection for GLP-1-based pharmacotherapy for weight management across the binge eating spectrum
skipped — LLM skipped (--skip-llm)
- ctis·2025-523873-41-00·Authorised, ongoing·A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity
skipped — LLM skipped (--skip-llm)
- ctis·2025-524612-11-00·Authorised, ongoing·Effect of an adjunctive intervention on the tolerability of semaglutide in overweight adults without diabetes: a prospective, randomised, double-blind, single-centre, placebo-controlled clinical trial (SEMTOL)
skipped — LLM skipped (--skip-llm)
- ctis·2025-524052-58-00·Authorised, ongoing·Multiple Dose Study of RO7795068 and its effect on Gastric Emptying, and on PK of Oral Contraceptives
skipped — LLM skipped (--skip-llm)
- ctis·2024-520446-31-00·Authorised, recruiting·Efficacy and safety of NNC0487-0111 s.c. once-weekly compared to semaglutide s.c. once-weekly in participants with overweight or obesity, and type 2 diabetes (AMAZE 8)
skipped — LLM skipped (--skip-llm)
- ctis·2025-523106-32-00·Authorised, ongoing·A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight and Type 2 Diabetes
skipped — LLM skipped (--skip-llm)
- ctis·2025-522744-40-00·Authorised·A research study to see how NNC0487-0111 affects the body’s energy use after a weight loss in adults living with obesity, compared to a low-calorie diet or placebo
skipped — LLM skipped (--skip-llm)
- ctis·2025-524921-42-00·Authorised, ongoing·A three-part first-in-human trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of GUB-UCN2 in healthy lean and obese participants and participants with T2D
skipped — LLM skipped (--skip-llm)
- ctis·2025-523486-17-00·Authorised, ongoing·A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living with Obesity or Overweight with Weight-Related Comorbidities Who Do Not Have Diabetes
skipped — LLM skipped (--skip-llm)
- ctis·2024-520440-42-00·Authorised, ongoing·Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with obesity (AMAZE 1)
skipped — LLM skipped (--skip-llm)
- ctis·2024-520441-23-00·Authorised, ongoing·Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and type 2 diabetes (AMAZE 2)
skipped — LLM skipped (--skip-llm)
- ctis·2025-523511-11-00·Authorised, ongoing·A Phase 3, Randomized, Active- and Placebo-Controlled, Partially-Blinded Study to Compare the Efficacy and Safety of KAI-9531 Administered Once Weekly Versus Semaglutide and Placebo in Participants Living with Obesity Who Do Not Have Diabetes
skipped — LLM skipped (--skip-llm)
- ctis·2023-509176-42-00·Authorised·Efficacy, safety and pharmacokinetics of cagrilintide s.c. 2.4 mg as monotherapy
and in combination with semaglutide s.c. 2.4 mg (CagriSema) once weekly for weight management
in children and adolescents with overweight or obesity
skipped — LLM skipped (--skip-llm)
- ctis·2025-523804-62-00·Authorised, ongoing·Efficacy and safety of NNC0487-0111s.c once weekly in participants with obesity who have reached target dose during run-in period (AMAZE12).
skipped — LLM skipped (--skip-llm)
- ctis·2024-511114-20-00·Authorised·SEMAFORCRANIO : Multicenter, double-blind, parallel, randomized controlled trial of the efficacy of semaglutide in hypothalamic obesity secondary to craniopharyngioma in children aged 12 to 17 years
skipped — LLM skipped (--skip-llm)
- ctis·2025-522486-29-01·Authorised·Impact of Oral Semaglutide on Platelet Reactivity in Patients with Diabetes Mellitus or Overweight with High Risk or established Cardiovascular Disease: the SEMA-PLAT Study
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Obesity due to congenital leptin deficiency — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("Obesity due to congenital leptin deficiency" OR "Congenital Leptin Deficiency" OR "obesity, morbid, due to leptin deficiency") OR ("LEP syndrome" OR "LEP-related")ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Obesity due to congenital leptin deficiency" OR "Congenital Leptin Deficiency" OR "obesity, morbid, due to leptin deficiency"
Study-type breakdown: 0 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (701) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-27T01:21:31.056Z
